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Summary
 
Human histocompatibility leukocyte antigen B27 is highly associated with the rheumatic dis-
eases termed spondyloarthropathies, but the mechanism is not known. B27 transgenic rats de-
velop a spontaneous disease resembling the human spondyloarthropathies that includes arthritis
and colitis. To investigate whether this disease requires the binding of specific peptides to B27,
we made a minigene construct in which a peptide from influenza nucleoprotein, NP383-391
(SRYWAIRTR), which binds B27 with high affinity, is targeted directly to the ER by the sig-
nal peptide of the adenovirus E3/gp19 protein. Rats transgenic for this minigene, NP1, were
made and bred with B27 rats. The production of the NP383-391 peptide in B27
 
1
 
NP1
 
1
 
 rats
was confirmed immunologically and by mass spectrometry. The NP1 product displaced 
 
z
 
90%
of the 
 
3
 
H-Arg-labeled endogenous peptide fraction in B27
 
1
 
NP1
 
1
 
 spleen cells. Male
B27
 
1
 
NP1
 
1
 
 rats had a significantly reduced prevalence of arthritis, compared with B27
 
1
 
NP
 
2
 
males or B27
 
1
 
 males with a control construct, NP2, whereas colitis was not significantly af-
fected by the NP1 transgene. These findings support the hypothesis that B27-related arthritis
requires binding of a specific peptide or set of peptides to B27, and they demonstrate a method
for efficient transgenic targeting of peptides to the ER.
Key words: human histocompatibility leukocyte antigen B27 • transgenic rat • antigenic 
peptide • arthritis • mass spectrometry
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LA-B27 refers to a group of closely related alleles of
the HLA-B locus that shows strong genetic predispo-
sition to the rheumatic diseases termed spondyloarthropa-
thies (1, 2). The association of B27 with these disorders has
been known for 25 years, but the molecular mechanism
remains to be identified. The known physiologic function
of class I MHC molecules such as B27 is to present peptide
antigens, predominantly of intracellular origin, to the im-
mune system (3, 4), and it has been hypothesized that the
role of B27 in disease pathogenesis involves presentation
of one or more “arthritogenic” peptides (5). It has been
difficult, however, to find strong experimental support for
this hypothesis. Most of the T cells isolated from patients
with B27-related disease that are reactive with implicated
pathogens have been of the MHC class II–restricted CD4
variety (6), although occasional CD8
 
1
 
 B27-restricted clones
have been described (7). Results from studies of B27 trans-
genic rodents that develop spontaneous arthritis have also
not established a definite role for CD8
 
1
 
 B27-restricted T
cells (8–11).
In the studies described here, we have specifically ad-
dressed the role of HLA-B27 in transgenic rats expressing
this molecule. These rats develop a spontaneous multisys-
tem disease that shares several pathologic features with the
human spondyloarthropathies, including arthritis and colitis
(8–10, 12–15). We provide evidence that the specificity of
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the peptide population bound to HLA-B27 in vivo has a
significant effect on at least one important aspect of the dis-
ease course in these rats, peripheral arthritis.
 
Materials and Methods
 
Rats.
 
The transgenic lines on a Lewis (LEW)
 
1
 
 background,
21-4H and 21-4L, each expressing HLA-B
 
*
 
2705 and human
 
b
 
2m, have been previously described (13, 15). The 21-4H line
(150 B27 gene copies, 90 h
 
b
 
2m gene copies) develops a sponta-
neous multisystem disease, whereas the 21-4L line (6 gene copies
each of B27 and h
 
b
 
2m), which has a lower transgene copy and
level of expression, remains completely healthy. The DA.33-3
line, expressing the B
 
*
 
2705/h
 
b
 
2m transgene locus of the 33-3
line (55 copies of B27, 66 copies of h
 
b
 
2m; references 13, 15) on a
DA background, has likewise been described (16, 17). The
LEW.33-3 line, not previously described, was produced by back-
crossing the 33-3 transgene locus 
 
.
 
10 generations onto the LEW
background. This line shows a phenotype similar to 21-4H, but
without neurologic manifestations (15).
Sprague Dawley (SD) founder rats transgenic for the NP1 and
NP2 peptide expression constructs, described below, were pro-
duced by pronuclear microinjection, as previously described (15).
All nontransgenic LEW and SD breeding stock was originally ob-
tained from Charles River, Inc. (Wilmington, MA).
 
Production of the NP1 and NP2 Minigene Constructs.
 
A modifi-
cation of the method described by Anderson et al. (18) was used
to make two minigenes as outlined in Fig. 1 
 
A
 
. Overlapping oli-
gonucleotides were synthesized to encode a 27mer peptide con-
taining the 18mer signal sequence, MRYMILGLLALAAVC-
SAA, of the adenovirus protein E3/gp19K (19) at the NH
 
2
 
terminus, and the 9mer influenza A nucleoprotein, NP383-391
(SRYWAIRTR) (20), at the COOH terminus. 40 ng each of the
oligonucleotides were annealed, made fully double stranded with
Klenow enzyme and dNTPs, and then amplified by PCR with
oligonucleotide primers containing SalI and BamHI restriction
sites at the 5
 
9
 
 and 3
 
9
 
 ends, respectively. These sites were used to
clone the minigene into the expression vector pHSE3
 
9
 
 (21) under
the control of the H-2K
 
b
 
 promoter, as shown in Fig. 1 
 
B
 
. This
construct is hereafter referred to as the NP1 minigene. A control
minigene construct, hereafter called the NP2 minigene, was sim-
ilarly produced, in which the codon for Arg at P2 of the
NP383-391 peptide was replaced by Leu to encode the peptide
SLYWAIRTR, which does not bind to B27 (22). The DNA
sequences of the minigene inserts were confirmed to be correct
by dideoxy sequencing. Preliminary transfection experiments in
B27
 
1
 
 human and mouse cells lines confirmed expression of
mRNA from both constructs and immunologically authentic
SRYWAIRTR from NP1 (data not shown). For microinjection
into fertilized rat eggs, the NP1 and NP2 inserts were excised
from the vector at the flanking XhoI sites.
 
Northern Analysis.
 
Northern blot hybridization of whole cel-
lular RNA was carried out on cell lines and rat tissues as previ-
ously described (13). Hybridization specific for the NP1 and NP2
constructs was carried out with a 
 
32
 
P-labeled 1.6-kb BamHI-PstI
fragment from the human 
 
b
 
-globin gene 3
 
9
 
-untranslated region
contained within the pHSE3
 
9
 
 vector (21). Quantitation of
mRNA by normalization to 18S RNA was carried out as previ-
ously described (13).
 
Flow Cytometry.
 
Surface B27 expression on lymphoid cells
was detected by flow cytometry with the anti–HLA-B,C mAb
B1.23.2, as previously described (13, 15).
 
CTL Generation and Assays.
 
The expression of antigenic NP1
peptide was assayed in B
 
*
 
2705/h
 
b
 
2m-bearing transfected cell
lines or Con A–stimulated lymph node (LN) lymphoblasts by us-
ing these cells as labeled targets in a 4-h 
 
51
 
Cr-release assay with ef-
fectors from the B27-restricted, NP peptide-specific human CTL
line Q124 (23; the gift of Dr. W.E. Biddison, NIH, Bethesda
MD). CTL effectors were generated by stimulating Q124 cells
with irradiated B27
 
1
 
 human peripheral blood mononuclear cells
pulsed with NP peptide for 6 d in vitro, as previously described
(23).
Recognition of the B27-presented HY minor histocompatibil-
ity antigen by polyclonal rat CTL was assayed as previously de-
scribed (16, 17). The same protocol was modified to generate (
 
a
 
)
polyclonal CTL allospecific for HLA-B27 by priming nontrans-
genic DA rats with lymphoid cells from sex-matched line 21-4L
rats on a LEW background congenic for RT1
 
av1
 
 and (
 
b
 
) B27-
restricted NP peptide-specific CTL by priming 21-4L (B27
 
1
 
NP
 
2
 
)
recipients with B27
 
1
 
NP1
 
1
 
 transgenic lymphoid cells.
CTL assay of targets sensitized with HPLC-fractionated pep-
tides was carried out as previously described (17, 24). Cold target
competition experiments were carried out as previously described
(16, 17, 24). All incubations with synthetic NP383-391 peptide
were at 2–4 
 
m
 
M.
 
Peptide Analysis.
 
Metabolic labeling, peptide isolation, frac-
tionation by reverse phase HPLC, and sequence analysis by quad-
rupole time-of-flight mass spectrometry (QTOF/MS) were car-
ried out as previously described (17, 24).
 
IL-1
 
b
 
 Assay.
 
The IL-1
 
b
 
 content of proximal colon was as-
sayed by ELISA with polyclonal goat anti–rat IL-1
 
b
 
 antibodies, as
previously described (25).
 
Clinical Assessment.
 
Rats were scored twice a week, usually
without knowledge of their genotypes, for arthritis, diarrhea, and
other clinical manifestations of the B27/h
 
b
 
2m transgenic rats, as
previously described (8–10, 13, 15).
 
Histopathology.
 
Formalin-fixed, paraffin-embedded, hema-
toxylin- and eosin-stained sections of proximal colon and acid-
decalcified ankle joints were prepared as previously described (8).
Histologic colitis was graded on a semiquantitative scale of 0–4, as
previously described (25). All histologic assessment was done
without knowledge of the genotypes of the specimen donors.
 
Statistical Analysis.
 
Comparisons among groups of rats were
made by a 
 
x
 
2 
 
test, 
 
t
 
 test, ANOVA, or Wilcoxon rank sum test.
 
Results
 
Production of the NP1 and NP2 Transgenic Rat Lines.
 
The NP1 and NP2 minigene constructs were used to pro-
duce transgenic SD by pronuclear microinjection. Ge-
nomic integration of the NP1 and NP2 constructs was ob-
served in nine and six founders, respectively. Two NP1
lines, 293-5 and 300-5, and one NP2 line, 338-2, were es-
tablished. The relative transgene mRNA levels in spleen in
these three lines were 1.0, 1.3, and 3.9, respectively. In an
mRNA tissue survey in the 300-5 line, the highest mRNA
levels were found in thymus and spleen, with weaker ex-
pression in jejunum and liver (data not shown).
 
Immunologic Identification of the NP1 Transgene Product.
 
To test for the presence of the NP383-391 peptide in the
 
1
 
Abbreviations used in this paper:
 
 LEW, Lewis; LN, lymph node; SD,
Sprague Dawley. 
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NP1 rats, the NP1 and NP2 transgene loci were back-
crossed to the LEW background and crossed with the B27/
h
 
b
 
2m transgenic lines 21-4H, LEW.33-3, and 21-4L. B27
surface expression as detected by flow cytometry was not
significantly affected by the simultaneous expression of ei-
ther the NP1 or the NP2 transgene (data not shown). Con
A blast LN targets from the single and double transgenic
offspring were tested for lysis by the human CTL line,
Q124, which is specific for B27 and the NP383-391 pep-
tide. As shown in Fig. 2 
 
A
 
, the B27
 
1
 
NP1
 
1
 
 targets were
lysed well by the specific CTL, whereas the B27
 
1
 
NP
 
2
 
 and
B27
 
1
 
NP2
 
1
 
 targets were not lysed. Moreover, lysis of the
B27
 
1
 
NP1
 
1
 
 targets was inhibited by B27
 
1
 
NP
 
2
 
 cold targets
pulsed with synthetic NP383-391 peptide (see Fig. 2 
 
B
 
),
consistent with the predicted specificity of the transgene
product. In a separate experiment, LN and spleen cells
from a B27
 
1
 
NP1
 
1
 
 rat were used to prime an RT1-
matched B27
 
1
 
NP
 
2
 
 recipient, and subsequently to restimu-
late the primed LN cells in vitro, which were then tested
for lysis of the mouse lymphoma EL-4 cells transfected
with HLA-B27 and h
 
b
 
2m in the presence or absence of
added NP383-391 peptide. As shown in Fig. 2 
 
C
 
, CTL ef-
fectors were generated that were specific for B27 and the
added peptide, indicating that the NP1 transgene product is
presented by B27 in vivo.
 
HPLC Isolation and MS Sequencing of the NP1 Peptide.
 
To identify the NP1 product biochemically, B27 mole-
cules were immunoprecipitated from detergent lysates of
B27
 
1
 
NP1
 
1, B271NP2, and B271NP21 spleen cells, and
the bound peptides were dissociated in acid and fraction-
ated by reverse phase HPLC. When aliquots of the HPLC
fractions were tested for sensitization of B271 human C1R
targets, all of the immunologic activity was found in frac-
tion 83 from the B271NP11 peptides (Fig. 3 A), whereas
no activity was found in any of the B271NP2 (Fig. 3 B) or
B271NP21 (data not shown) peptide fractions.
Electrospray mass spectrometric analysis of the active frac-
tion from NP11 spleen indicated five peptides with molecu-
lar masses 1207.7, 1303.6, 1313.8, 1379.8, and 1473.7 (Fig.
4, top). The most abundant ion, of m/z 403.6, was selected
for tandem MS analysis and shown to correspond to the
[M13H]31 ion of the NP383-391 peptide, SRYWAIRTR
(Fig. 4, bottom). Analysis of the other four peptides indicated
that they were modifications of the SRYWAIRTR sequence
by adducts of 96, 106, 172, and 266 Da. Full characterization
of these adducts is in progress. It also remains to be determined
whether these modifications to the NP1 transgene product
occur in vivo or as a result of the purification procedure.
Estimates of Endogenous B27 Peptide Displacement by NP1.
To estimate the extent to which surface B27 molecules
were engaged by NP1-encoded peptides, spleen cells from
B271NP11, B271NP21, and B271NP2 rats were meta-
bolically labeled with 3H-Arg, and the peptides bound to
B27 were isolated and separated by RP-HPLC, as de-
scribed above. As shown in Fig. 5, B and C, the peptides
extracted from both B271NP2 and B271NP21 B27 mole-
cules eluted in a broad peak between fractions 30 and 70,
containing z98% of the total eluted 3H. This result was
similar to the pattern that we have previously reported for
endogenous B27-bound peptides in transgenic mouse
spleen eluted under the same conditions (24). In contrast,
as shown in Fig. 5 A, the B27-bound peptides from
B271NP11 spleen eluted in two peaks. The larger peak
was centered at the same position as the NP1-encoded
peptide product identified immunologically and confirmed
by mass spectrometry (Figs. 3 and 4). This peak represented
z87% of the total eluted radioactivity. The smaller peak,
containing z9% of the eluted counts, appeared to be an at-
tenuated version of the peak of endogenous peptides found
in the B271NP2 and B271NP21 eluates. These results
suggest that a z10-fold reduction in the usual B27-bound
endogenous peptide population occurs in the B271NP11
rats through displacement by NP1-encoded peptide.
To assess the functional consequences of NP1 expres-
sion, Con A blast targets were compared as targets for lysis
by B27-restricted anti-HY CTL and by anti-B27 alloge-
neic CTL. As shown in Fig. 6 A, male B271NP11 targets
were lysed by B27-restricted anti-HY CTL to only z50%
the level of male B271NP12 targets. Similar results were
seen with anti-B27 allospecific CTL (Fig. 6 B). These find-
Figure 1. Construction of the minigenes encoding the adenovirus E3/19K signal peptide and influenza NP383-391 peptide. (A) Procedure for gener-
ation of the double-stranded DNA insert. The indicated overlapping oligonucleotides were synthesized and annealed. Double stranded synthesis was
completed with Klenow enzyme, and the resulting construct was cleaved with SalI and BamHI and ligated into the expression vector pHSE39 (21). For
the NP2 minigene, the residue at P2 in the B27-binding epitope was changed from Arg to Leu by replacing the codon AGG with the codon TTG. This
substitution abrogates binding of the peptide to B27 (22). (B) Map of the complete construct for NP1 and NP2.880 Role for HLA-B27 Peptide Specificity in Arthritis in Transgenic Rats
ings indicate at least a twofold reduction of the endogenous
peptides antigenic in these respective systems as a result of
expression of the NP1 transgene locus.
Effects of the NP1 and NP2 Transgenes on Inflammatory Dis-
ease in B27 Rats. To test the effect of the NP1 and NP2
transgenic products on spontaneous clinical disease in rats,
the 293-5 and 300-5 NP1 lines and 338-2 NP2 line were
backcrossed to the disease-prone LEW lines 21-4H and
LEW.33-3, and the double transgenic B271NP1 and single
transgenic B271NP2 offspring were observed for the disease
manifestations characteristic of the 21-4H line (13, 15). The
clinical data from all of the rats observed to age 6 mo are
shown in Table 1. The rats were of backcross generation
N2-N6 to the LEW background (median generation N4
for all three genotypes, NP11, NP21, and NP2; mean 6
SD 3.8 6 1.2, 3.7 6 1.0, and 3.5 6 0.5, respectively).
Almost all of the rats developed diarrhea, and there was
no significant difference among the groups regarding the
age of onset of the diarrhea or its maximum severity (data
not shown). Similarly, there was no difference among the
groups in which the IL-1b content of proximal colon was
measured at sacrifice. Histologic examination of proximal
colon was carried out on a subset of the males. There was a
trend toward more severe disease in the groups lacking
NP1, but this was not statistically significant (data not
shown). WBC measurements at 3 mo of age showed no
difference among the groups (Table 1), and there was simi-
larly no difference in the pattern of WBC elevation upon
serial measurements (data not shown).
The one parameter showing a significant difference
among the groups was the prevalence of arthritis, with only
6 of 25 NP11 male rats developing arthritis during observa-
tion to age 6 mo, compared with 15 of 22 NP2 and 4 of 7
NP21 controls (P 5 0.005 for NP11 versus NP12).
Among the female NP11 and NP2 rats, the prevalence of
arthritis was very low (1 of 20 and 3 of 22, respectively),
Figure 2. The NP1 transgene construct directs expression of antigeni-
cally authentic NP1 peptide. (A) Con A–stimulated LN lymphoblast tar-
gets from the indicated transgenic rats were tested for lysis by the human
CTL line Q124, which is specific for HLA-B27 and the NP383-391 pep-
tide. Only cells from rats carrying both the B27/hb2m and NP1 trans-
gene loci were lysed significantly. (B) Con A blast targets from a B271
NP12 rat were pulsed with synthetic NP peptide (10 nM), then washed
and tested for lysis by the Q124 CTL line at an E:T of 5:1, in the pres-
ence of varying concentrations of the indicated unlabeled (cold) targets.
Lysis was efficiently inhibited by double transgenic B271NP11 targets
and by B271 targets pulsed with synthetic NP peptide. (C) B271NP12
rats were immunized in vivo with cells from RT1-matched B271NP11
rats, and the immune LN cells were restimulated in an MLR. The result-
ing CTL effectors lysed B27/hb2m-transfected mouse EL-4 tumor cells
to which authentic NP1 peptide, but not NP2 peptide, had been added.
Figure 3. Isolation and immunologic identification of NP peptide from
transgenic rats. B27 molecules were immunoprecipitated from 108
B271NP11 (A) and B271NP2 (B) Con A–stimulated spleen cells and the
bound peptides were extracted with 0.1% TFA and separated by RP-
HPLC. One-tenth of each fraction was added to 5,000 51Cr-labeled B271
C1R cells, which were then tested for lysis by 2.5 3 104 line Q124 CTL
effectors. Lysis above background was seen only with the peptides from
the B271NP11 cells, with all of the immunologic activity in fraction 83.881 Zhou et al.
whereas 2 of 6 NP21 females developed arthritis. Among
rats developing arthritis, there was no difference in the age
of onset or severity of the arthritis among the six groups.
Among the NP11 males, arthritis was observed in 4 of 17
rats backcrossed to 21-4H and 2 of 8 backcrossed to
LEW.33-3. Among the NP2 males, arthritis was observed
in 10 of 13 backcrossed to 21-4H and 5 of 9 backcrossed to
LEW.33-3. Among NP21 males, the corresponding num-
bers were 2 of 3 and 2 of 4. Among the joints assessed his-
tologically, 26 were from rats that never showed clinically
evident arthritis, and these are listed in Table 1. Only three
of these sections showed any microscopic lesions, two from
NP2 females and one from an NP21 male.
A subsequent cohort of 300-5 (NP1) 3 21-4H and 338-2
(NP2) 3 21-4H rats, of backcross generations N5-N7 to
LEW, was observed to age 4 to 6 mo for arthritis, which
Figure 4. Mass spectrometric
analysis of the immunologically
active NP fraction, as shown in
Fig. 3. (Top) Electrospray MS
spectrum. The [M13H]31 ions
of components A–E are indi-
cated, with the charge state evi-
dent from the m/z ratio separa-
tion of the isotopic components.
Corresponding [M12H]21 and
[M14H]41 ions were also ob-
served outside the m/z range
shown. (Bottom) Product ion
spectrum recorded during tan-
dem MS analysis. The selected
precursor ion was m/z 403.6
([M13H]31). Fragment ions are
designated using the nomencla-
ture of Biemann (41). Confirma-
tory evidence was obtained from
the product ion spectrum of m/z
604.8 ([M12H]21); b7
21 was ob-
served only in the latter spec-
trum.882 Role for HLA-B27 Peptide Specificity in Arthritis in Transgenic Rats
again was seen almost exclusively in males. Of the B271
males of this group, arthritis was observed in 1 of 4 NP11, 3
of 4 NP21, and 6 of 8 NP2 rats. Upon adding these results
to the tally shown in Table 1, the prevalence of arthritis was
found to be 7 of 29 in NP11 rats, and 28 of 41 in NP12 rats
(x2 with Yates’ correction 5 11.54, P , 0.0006).
Discussion
The prevalence of arthritis was significantly reduced in
male B27/hb2m transgenic rats also carrying a transgene
targeting the influenza A NP383-391 peptide to the ER,
compared with B27/hb2m rats lacking the NP1 transgene.
In the B27/hb2m female littermates, the prevalence of ar-
thritis was very low in both the NP11 and NP2 groups.
Arthritis is typically more common in male B27/hb2m rats
than in the females (13, 15). The sex difference in these
studies was more pronounced than usual, and the low
prevalence of arthritis in the NP2 females made it difficult
to draw any conclusions from a comparison of the groups
of female rats. Nonetheless, considering both sexes, of the
rats shown in Table 1, 6 out of 13 rats transgenic for the
control NP2 construct developed arthritis, providing evi-
dence that the suppression of arthritis in the NP11 rats was
not a nonspecific artifact of the NP1 transgene construct it-
self. This was further supported by a subsequent cohort, in
which 3 of 4 NP21 males developed arthritis, and overall,
there was a significant difference in arthritis prevalence be-
tween NP11 and NP21 males (7/29 vs. 7/11). The data
from the males thus suggest that the specificity of the pep-
tides bound to B27 in vivo is a key factor in the pathogen-
esis of spontaneous arthritis in B27/hb2m transgenic rats.
Although the B27 transgenic lines were produced in in-
bred rats (15), the NP constructs were introduced into SD
eggs because of the far greater efficiency of the procedure
in this outbred strain compared with inbred rat strains, par-
ticularly LEW. It is of some potential concern that the rats
in this study were not completely inbred. However, the
correlation of NP1 with reduced prevalence of arthritis is
statistically quite significant and there was no significant ef-
fect of either the backcross generation or the origin of the
B27/hb2m transgene locus (21-4H or 33-3) on the preva-
lence of arthritis in any of the three NP genotypes. The
finding of a lower prevalence of arthritis in NP11 rats com-
pared with NP21 and NP2 rats in a subsequent, more ex-
tensively backcrossed cohort further supports this concept.
Overall, the data support the conclusion of a peptide-spe-
cific suppression of arthritis.
Sequence analysis of the peptides in the one immuno-
logically active HPLC fraction of the peptides eluted from
B27 molecules of B271NP11 rats confirmed that the pep-
Figure 5. The NP1 transgene construct dramatically alters the profile of peptides bound to B27. Spleen cells from NP11 (A), NP2 (B), and NP21 (C)
LEW.33-3 rats were metabolically labeled with 3H-Arg, and the B27 molecules were immunoprecipitated from detergent lysates of the labeled cells, as
previously described (24). The bound peptides were eluted and separated by RP-HLPC, as in Fig. 3, A and B, and the resulting fractions counted for 3H.
Total 3H cpm in the B27 immunoprecipitates were (31027): NP11 2.75, NP21 3.00, NP2 2.75. Total 3H cpm in the peptide pools eluted from B27
were (31024): NP11 6.5, NP21 8.4, NP2 6.8.
Figure 6. Expression of the NP1 transgene construct reduces recogni-
tion of other B27-presented peptides. (A) CTL against the male-specific
HY minor histocompatibility antigen presented by HLA-B27 were gen-
erated in LEW transgenic rats as previously described (10, 16, 17, 24).
These were tested for lysis of Con A lymphoblasts from male rats carrying
the indicated transgenes. The rats were from a backcross of the SD 300-5
line to the DA.33-3 line, and therefore did not share any RT1 alleles with
the effectors. (B) Allospecific CTL were generated by in vivo immuniza-
tion of nontransgenic DA rats with cells from sex-matched B27/hb2m
LEW 21-4L rats congenic for RT1av1, and the immune LN cells were
similarly restimulated in an MLR. The CTL were tested for lysis of the
Con A blast target cells described in A.883 Zhou et al.
tide species in this fraction all derived from the transgene,
both the expected NP383-391 peptide and an unexpected
series of chemical derivatives of this peptide. Determina-
tion of the origin and nature of these derivatives is in
progress. However, for the main purpose of this study, the
most significant characteristic of these derivatives is that all
were bound to B27.
The pattern of 3H-labeled peptides eluted from B27
molecules differed dramatically between the NP11 and
NP2 or NP21 rats, and the findings suggested that z90%
of the endogenous peptides normally binding to B27 were
displaced by the NP1-encoded peptide. This was supported
by the substantial inhibition of CTL recognition of endog-
enous B27-presented peptides in B271NP11 targets. The
reduction of endogenous antigenic peptide seen in these
experiments was probably greater than twofold, because of
the sigmoidal nature of peptide/CTL lysis dose response
curves (17, 26). These results indicate that the strategy to
displace endogenous B27-bound peptides through expres-
sion of the transgene construct was successful. To our
knowledge, this is the first report of the targeting of a
highly expressed MHC class I–presented peptide antigen to
the ER via a transgene.
Although arthritis was suppressed in the NP11 rats, there
was no pronounced effect of this transgene construct on
gut inflammation. This finding is consistent with the possi-
bility that peptide specificity is of less overall relevance in
the development of colitis than of arthritis. However, the
finding does not necessarily preclude the need for peptide
specificity in the pathogenesis of colitis in the B27 trans-
genic rats. We have previously shown that germ-free B27
transgenic rats do not develop either gut inflammation or
arthritis (14, 25). Since luminal bacteria are abundant in the
gastrointestinal tract, it may be that in the gut but not in
the joint the generation of a putative B27-presented, dis-
ease-related antigenic peptide from an intracellular bacteria
is quantitatively sufficient to overcome the blockade im-
posed by the NP1 transgene. Alternatively, class I molecules
are capable of acquiring exogenous antigen (27), and if this
were the mechanism operating in the gut to induce B27-
related colitis, then in this case the nature of the peptides
acquired by B27 molecules in the ER, whether endoge-
nous or arising from the NP1 transgene, would presumably
be relatively unimportant. Although the spondyloarthropa-
thies in humans are strongly associated both with HLA-
B27 and with gut inflammation (which can range from
subclinical histologic changes to classic ulcerative colitis or
Crohn’s disease), there is no particular association between
HLA-B27 and classic inflammatory bowel disease in the
absence of arthritis (reviewed in reference 28). This is quite
different from the case of the disease-prone lines of the B27
transgenic rats, in which marked colitis has virtually a 100%
prevalence and usually develops before any arthritis is seen
(13). In this respect, the disease in rats most resembles hu-
man reactive arthritis that arises after intestinal infection.
Based on these observations, as well as on the findings that
both the gut disease and arthritis in the B27 rats are abro-
grated by the germ-free state (14) and by the DA genetic
background (29 and Taurog, J.D., S.D. Maika, N. Sat-
umtira, M.L. Dorris, I.L. McLean, W.A. Simmons, A.T.
Table 1. Clinical Manifestations in NP11, NP21, and NP2 Rats Carrying a Disease-prone B27/hb2m Transgene Locus
Sex Genotype Total
WBC at 3 mo
3 1023
Joint swelling
Microscopic joint
abnormality*
Diarrhea
Proximal colon
IL-1b n affected Age onset n affected Age onset
n d d pg/mg
Male NP11 25 27 6 10‡ 6 128 6 25 0/7 24 76 6 25 19 6 16
(21)§ (8)
NP21 7 28 6 12 4 114 6 29 1/2 7 87 6 21 ND
(5)
NP2 22 20 6 9 15 128 6 22 0/3 21 86 6 24 35 6 35
(13) (11) (19) (7)
Female NP11 20 31 6 12 1 145 0/4 20 69 6 15 22 6 8
(19) (2)
NP21 6 23 6 5 2 146 6 6 0/3 6 76 6 9N D
(5)
NP2 22 25  6 6 3 142 6 26 2/7 22 79 6 16 24 6 4
(17) (3)
Arthritis was found in 6 of 25 NP11 males and 19 of 29 NP12 males (x2 with Yates’ correction 5 7.71, P 5 0.005).
*Number of rats with no clinically evident arthritis that showed microscopic joint abnormalities (mild periarthritis and peritendonitis in one NP21
male and mild synovitis in two NP2 females), out of the 26 examined.
‡Mean 6 SD (WBC of healthy 21-4L rats of this age average 9,500 6 1,500).
§Number of rats for which a determination was made.884 Role for HLA-B27 Peptide Specificity in Arthritis in Transgenic Rats
Le, A. Sayad, J.B. Splawski, J.A. Richardson, and R.E.
Hammer, manuscript in preparation), we favor a model in
which arthritis in the rats is dependent upon gut inflamma-
tion. This model would not require the B27 transgene
product to play the same role in the pathogenesis of the gut
and joint disease, and the evidence from the current study
at least suggests the possibility that it in fact does not. Con-
sistent with this interpretation is the finding that rats trans-
genic for a B*2705 gene with a mutation in the B pocket
(67Cys®Ser) develop severe gut disease but very little ar-
thritis (Taurog, J.D., S.D. Maika, N. Satumtira, M.L. Dor-
ris, I.L. McLean, W.A. Simmons, A.T. Le, A. Sayad, J.B.
Splawski, J.A. Richardson, and R.E. Hammer, manuscript
in preparation).
Because this disease has only been observed in rats with
high gene copy number and supraphysiologic expression of
the B27 and hb2m transgenes (13, 15), it has been of some
concern whether the role of B27 in the rat disease is similar
to that in the human spondyloarthropathies. There is no
evidence that the disease is simply an artifact of high HLA
class I expression, since control rats with equally high ex-
pression of HLA-B7 or HLA-Cw6 do not develop this dis-
ease and the overwhelming majority of these rats remain
healthy (30 and Taurog, J.D., S.D. Maika, N. Satumtira,
M.L. Dorris, I.L. McLean, W.A. Simmons, A.T. Le, A.
Sayad, J.B. Splawski, J.A. Richardson, and R.E. Hammer,
manuscript in preparation). Moreover, as already noted, the
rat disease resembles the human spondyloarthropathies in
its relationship to the gut flora, modifying background
genes, and a requirement for T cells, as well as in pheno-
type. Previous investigation of the cellular pathogenesis has
suggested that both CD41 and CD81 can separately trans-
fer disease to athymic B27 transgenic rats (9). However, the
recipients of these transferred cells predominantly exhibited
gut and skin disease, with very little arthritis. Thus, it is not
yet clear which effector cells mediate arthritis in these rats.
Moreover, even if CD4 cells were found to be effectors of
arthritis, this would not preclude the requirement for the
antecedent participation of B27-restricted, peptide specific,
CD8 T cells, for example through a mechanism involving
epitope spreading (31). Part of the rationale for the present
study was the observation that high B27 expression was re-
quired for disease expression. This suggested that an arthrito-
genic peptide may be presented above a critical threshold
level in the high transgene copy rats. If so, it would be pre-
dicted that disease would be prevented or suppressed by re-
ducing the level of presentation of this putative peptide. As
noted above, the present data suggest that distinct cellular
processes and molecular recognition events may be operat-
ing in the pathogenesis of the arthritis and gut disease in the
B27 rats, and they provide the best evidence to date that
B27 presents a specific peptide at some stage in the devel-
opment of arthritis in these animals.
Further work will be needed to gain insight into the
mechanism by which arthritis is suppressed. The effect may
be occurring in the peripheral immune system and/or at
the level of thymic selection, and these possibilities can be
better investigated once the NP lines are sufficiently inbred
to carry out thymus graft and cell transfer experiments. Fi-
nally, it remains formally possible that the critical influence
of the NP1 transgene product on disease pathogenesis is not
exerted through displacement of a peptide or set of peptides
that is recognized by conventional peptide-specific T cells,
but rather on some aspect of the metabolism of the B27 mol-
ecules in a critical intracellular compartment. This might
make a difference, for example, if the critical role of B27 in
arthritis were to provide a B27-derived peptide presented by
MHC class II, as has been hypothesized (32). However, the
similar levels of surface-expressed B27 and of 3H-Arg incor-
porated into immunoprecipitated B27 in the NP11, NP21,
and NP2 rats tend to weigh against this possibility.
There are 12 known subtypes of HLA-B27. Epidemio-
logic studies of disease association have been carried out for
seven of them, B*2702, -03, -04, -05, -06, -07, and -09;
the others are too rare and/or too recently discovered to
have been studied or to have yielded susceptibility data (1,
2, 33). Of these seven subtypes, two, HLA-B*2706 and
-B*2709, have shown little or no association with the
spondyloarthropathies in recent epidemiologic studies (33–
36). These two subtypes differ from the disease-associated
subtypes at position 116, in the floor of the F-pocket of the
peptide binding groove, and B*2706 also differs at an adja-
cent floor position, 114. The major effect of these differ-
ences would be expected to be exerted on the spectrum of
peptides accommodated by the binding groove, particularly
at the peptide COOH terminus, and indeed significant dif-
ferences in this regard have been identified (37, 38). The
data from these recent studies of the B27 subtypes and from
the experiments in B27 rats reported here thus both sup-
port the “arthritogenic peptide” hypothesis. Similar struc-
tural correlations with genetic epidemiology have also im-
plicated peptide binding in the pathogenetic role of other
disease-associated HLA alleles (reviewed in 39).
Studies of the B27 subtypes have also indicated that the
peptides eluted from the disease-prone subtypes B*2702,
-04, and -07, unlike those from B*2705 (and also -01, -03,
and -10), do not include peptides with positively charged
COOH termini. These data suggest that if there is a com-
mon arthritogenic peptide bound by all of the disease-prone
subtypes, it most likely carries an aliphatic or aromatic
COOH terminus (reviewed in references 1, 2). This may
explain our previous observation that polymorphism of the
MHC-linked peptide transporters in the rat had no signifi-
cant effect on disease in B*2705 transgenic rats, despite an
appreciable influence on peptide presentation by B27 (10),
since this polymorphism would not necessarily affect trans-
port of peptides with noncharged COOH termini (24, 40).
In summary, this study in transgenic rats provides evi-
dence consistent with recent findings in humans that the
peptide specificity of B27 is critical to its role in enhancing
susceptibility to the spondyloarthropathies. Further work in
the B27 transgenic rat system may help to identify the rele-
vant peptides and the mechanism by which they induce ar-
thritis. This study also suggests the potential feasibility of
gene therapy specifically targeting peptides to particular
MHC alleles.885 Zhou et al.
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